Thompson Investment Management Inc. Purchases 247 Shares of Amgen, Inc. (NASDAQ:AMGN)
Thompson Investment Management Inc. lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 1.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,144 shares of the medical research company’s stock after acquiring an additional 247 shares during the quarter. Thompson Investment Management Inc.’s holdings in Amgen were worth $4,285,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Thomasville National Bank grew its stake in Amgen by 2.7% in the second quarter. Thomasville National Bank now owns 24,500 shares of the medical research company’s stock valued at $4,515,000 after purchasing an additional 653 shares during the last quarter. Private Trust Co. NA grew its stake in Amgen by 1.9% in the second quarter. Private Trust Co. NA now owns 5,678 shares of the medical research company’s stock valued at $1,046,000 after purchasing an additional 104 shares during the last quarter. LVM Capital Management Ltd. MI grew its stake in Amgen by 1.3% in the second quarter. LVM Capital Management Ltd. MI now owns 61,058 shares of the medical research company’s stock valued at $11,252,000 after purchasing an additional 792 shares during the last quarter. Baystate Wealth Management LLC grew its stake in Amgen by 1,432.0% in the second quarter. Baystate Wealth Management LLC now owns 1,532 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 1,432 shares during the last quarter. Finally, Fulton Bank N.A. grew its stake in Amgen by 2.5% in the second quarter. Fulton Bank N.A. now owns 14,196 shares of the medical research company’s stock valued at $2,616,000 after purchasing an additional 345 shares during the last quarter. Hedge funds and other institutional investors own 76.33% of the company’s stock.
AMGN has been the topic of several analyst reports. Sanford C. Bernstein initiated coverage on Amgen in a research note on Monday, October 14th. They issued an “outperform” rating on the stock. Cowen set a $231.00 target price on Amgen and gave the company a “buy” rating in a research note on Sunday, September 29th. Mizuho reiterated a “hold” rating and issued a $212.00 target price on shares of Amgen in a research note on Sunday, September 29th. Cantor Fitzgerald upgraded Amgen from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $230.00 to $255.00 in a research note on Tuesday. Finally, Evercore ISI reiterated a “hold” rating on shares of Amgen in a research note on Sunday, August 11th. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Amgen has an average rating of “Buy” and a consensus price target of $219.56.
Shares of AMGN stock traded up $3.12 during trading hours on Friday, reaching $221.11. 2,069,900 shares of the company’s stock were exchanged, compared to its average volume of 2,911,719. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $221.25. The stock has a market cap of $127.80 billion, a PE ratio of 15.35, a PEG ratio of 2.21 and a beta of 1.09. The company has a current ratio of 2.89, a quick ratio of 2.59 and a debt-to-equity ratio of 2.54. The stock’s fifty day moving average price is $202.27 and its two-hundred day moving average price is $188.68.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.63 billion. During the same quarter in the previous year, the firm earned $3.69 earnings per share. The company’s revenue was down 2.8% on a year-over-year basis. On average, equities analysts expect that Amgen, Inc. will post 14.44 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Friday, November 15th will be given a $1.45 dividend. The ex-dividend date is Thursday, November 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.62%. Amgen’s dividend payout ratio is currently 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: What is insider trading?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.